Catia Marzolini

10.6k total citations · 5 hit papers
130 papers, 6.0k citations indexed

About

Catia Marzolini is a scholar working on Infectious Diseases, Virology and Pediatrics, Perinatology and Child Health. According to data from OpenAlex, Catia Marzolini has authored 130 papers receiving a total of 6.0k indexed citations (citations by other indexed papers that have themselves been cited), including 84 papers in Infectious Diseases, 39 papers in Virology and 39 papers in Pediatrics, Perinatology and Child Health. Recurrent topics in Catia Marzolini's work include HIV/AIDS drug development and treatment (71 papers), HIV Research and Treatment (39 papers) and Pharmacological Effects and Toxicity Studies (35 papers). Catia Marzolini is often cited by papers focused on HIV/AIDS drug development and treatment (71 papers), HIV Research and Treatment (39 papers) and Pharmacological Effects and Toxicity Studies (35 papers). Catia Marzolini collaborates with scholars based in Switzerland, United Kingdom and United States. Catia Marzolini's co-authors include Laurent A. Décosterd, Thierry Buclin, Amalio Telenti, Jérôme Biollaz, David Back, Gilbert Greub, Manuel Battegay, Richard B. Kim, Saye Khoo and Sara Gibbons and has published in prestigious journals such as The Lancet, PLoS ONE and Hepatology.

In The Last Decade

Catia Marzolini

122 papers receiving 5.8k citations

Hit Papers

Polymorphisms in human MDR1 (P-glycoprotein): recent adva... 2001 2026 2009 2017 2004 2001 2002 2022 2023 200 400 600
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Polymorphisms in human MDR1 (P-glycoprotein): recent advances and clinical relevance
    2004 729 citations Catia Marzolini profile →
  2. Efavirenz plasma levels can predict treatment failure and central nervous system side effects in HIV-1-infected patients
    2001 687 citations Catia Marzolini, Laurent A. Décosterd et al. profile →
  3. Response to antiretroviral treatment in HIV-1-infected individuals with allelic variants of the multidrug resistance transporter 1: a pharmacogenetics study
    2002 535 citations Jacques Fellay, Catia Marzolini et al. profile →
  4. Recommendations for the Management of Drug–Drug Interactions Between the COVID‐19 Antiviral Nirmatrelvir/Ritonavir (Paxlovid) and Comedications
    2022 162 citations Catia Marzolini, Daniel R. Kuritzkes et al. profile →
  5. Major revision version 12.0 of the European AIDS Clinical Society guidelines 2023
    2023 75 citations Alexandra Calmy, Catia Marzolini et al. profile →

Peers

Catia Marzolini
Saye Khoo United Kingdom
Edward P. Acosta United States
Francesca Aweeka United States
Adrian S. Ray United States
Jean‐Marc Tréluyer France
Richard M. W. Hoetelmans Netherlands
Richard Bertz United States
Marta Boffito United Kingdom
Brian P. Kearney United States
Richard C. Brundage United States
Saye Khoo United Kingdom
Catia Marzolini
Citations per year, relative to Catia Marzolini Catia Marzolini (= 1×) peers Saye Khoo

Countries citing papers authored by Catia Marzolini

Since Specialization
Citations

This map shows the geographic impact of Catia Marzolini's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Catia Marzolini with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Catia Marzolini more than expected).

Fields of papers citing papers by Catia Marzolini

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Catia Marzolini. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Catia Marzolini. The network helps show where Catia Marzolini may publish in the future.

Co-authorship network of co-authors of Catia Marzolini

This figure shows the co-authorship network connecting the top 25 collaborators of Catia Marzolini. A scholar is included among the top collaborators of Catia Marzolini based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Catia Marzolini. Catia Marzolini is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Carrara, Sandro, Nicolas Widmer, Laurent A. Décosterd, et al.. (2025). Therapeutic Drug Monitoring and Point-of-Care Technologies: Opportunities and Current Challenges. Therapeutic Drug Monitoring. 48(1). 42–53. 1 indexed citations
2.
Marzolini, Catia, et al.. (2025). Therapeutic drug monitoring of Janus kinase inhibitors for precision dosing: where do we stand ?. Expert Review of Clinical Pharmacology. 18(10). 753–769. 1 indexed citations
3.
4.
5.
Battegay, Manuel, et al.. (2024). Development of a physiologically‐based pharmacokinetic model to simulate the pharmacokinetics of intramuscular antiretroviral drugs. CPT Pharmacometrics & Systems Pharmacology. 13(5). 781–794. 7 indexed citations
6.
Marzolini, Catia, et al.. (2024). Is Nonsustained Viral Suppression With Long-Acting Cabotegravir and Rilpivirine Really Independent of Drug Levels?. Clinical Infectious Diseases. 81(1). e4–e5. 2 indexed citations
7.
Bernardini, Claudia, Wolfgang Bauer, Stefan Scholten, et al.. (2024). Long-Term Treatment Success with Bictegravir/Emtricitabine/Tenofovir Alafenamide (BIC/FTC/TAF). 1 indexed citations
8.
Marzolini, Catia, et al.. (2024). Drug-drug interactions potential with the HIV-1 capsid inhibitor lenacapavir. Expert Opinion on Drug Metabolism & Toxicology. 21(2). 161–172. 2 indexed citations
9.
Stader, Felix, et al.. (2024). Effect of Obesity on the Exposure of Long-acting Cabotegravir and Rilpivirine: A Modeling Study. Clinical Infectious Diseases. 79(2). 477–486. 10 indexed citations
10.
Esteban-Cantos, Andrés, Christian Thorball, Berta Rodés, et al.. (2023). Epigenetic ageing accelerates before antiretroviral therapy and decelerates after viral suppression in people with HIV in Switzerland: a longitudinal study over 17 years. The Lancet Healthy Longevity. 4(5). e211–e218. 21 indexed citations
11.
Marzolini, Catia, Katharina Rentsch, Marcel Stoeckle, et al.. (2023). Switch from a ritonavir to a cobicistat containing antiretroviral regimen and impact on tacrolimus levels in a kidney transplant recipient. Virology Journal. 20(1). 89–89.
12.
Stader, Felix, et al.. (2023). Management of Drug Interactions with Inducers: Onset and Disappearance of Induction on Cytochrome P450 3A4 and Uridine Diphosphate Glucuronosyltransferase 1A1 Substrates. European Journal of Drug Metabolism and Pharmacokinetics. 48(4). 353–362. 7 indexed citations
13.
Marzolini, Catia, Matthias Cavassini, Dominique L. Braun, et al.. (2023). Effect of SLCO1B1 c.521T>C polymorphism on the lipid response to statins in people living with HIV on a boosted protease inhibitor‐containing regimen. British Journal of Clinical Pharmacology. 89(9). 2739–2746.
14.
Munting, Aline, Matthias Cavassini, Dominique L. Braun, et al.. (2022). Real-Life Therapeutic Concentration Monitoring of Long-Acting Cabotegravir and Rilpivirine: Preliminary Results of an Ongoing Prospective Observational Study in Switzerland. Pharmaceutics. 14(8). 1588–1588. 10 indexed citations
15.
Courlet, Perrine, Monia Guidi, Matthias Cavassini, et al.. (2021). Population pharmacokinetic modelling to quantify the magnitude of drug-drug interactions between amlodipine and antiretroviral drugs. European Journal of Clinical Pharmacology. 77(7). 979–987. 6 indexed citations
16.
Courlet, Perrine, Laurent A. Décosterd, Matthias Cavassini, et al.. (2020). Influence of Drug–Drug Interactions on the Pharmacokinetics of Atorvastatin and Its Major Active Metabolite ortho-OH-Atorvastatin in Aging People Living with HIV. Clinical Pharmacokinetics. 59(8). 1037–1048. 8 indexed citations
17.
Courlet, Perrine, Monia Guidi, Matthias Cavassini, et al.. (2019). Escitalopram population pharmacokinetics in people living with human immunodeficiency virus and in the psychiatric population: Drug–drug interactions and probability of target attainment. British Journal of Clinical Pharmacology. 85(9). 2022–2032. 8 indexed citations
18.
Sundermann, Erin E., Kristine M. Erlandson, Caitlin N. Pope, et al.. (2019). Current Challenges and Solutions in Research and Clinical Care of Older Persons Living with HIV: Findings Presented at the 9th International Workshop on HIV and Aging. AIDS Research and Human Retroviruses. 35(11-12). 985–998. 10 indexed citations
19.
Krishnamurthy, Partha, Matthias Schwab, Kazumasa Takenaka, et al.. (2008). Transporter-Mediated Protection against Thiopurine-Induced Hematopoietic Toxicity. Cancer Research. 68(13). 4983–4989. 116 indexed citations
20.
Ribaudo, Heather J., David W. Haas, C. Tierney, et al.. (2006). Pharmacogenetics of Plasma Efavirenz Exposure after Treatment Discontinuation: An Adult AIDS Clinical Trials Group Study. Clinical Infectious Diseases. 42(3). 401–407. 170 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Saye Khoo Breakdown of academic impact, for papers by Edward P. Acosta Breakdown of academic impact, for papers by Francesca Aweeka Breakdown of academic impact, for papers by Adrian S. Ray Breakdown of academic impact, for papers by Jean‐Marc Tréluyer Breakdown of academic impact, for papers by Richard M. W. Hoetelmans Breakdown of academic impact, for papers by Richard Bertz Breakdown of academic impact, for papers by Marta Boffito Breakdown of academic impact, for papers by Brian P. Kearney Breakdown of academic impact, for papers by Richard C. Brundage
Rankless by CCL
2026